Compare Hims and Hers Health Inc (HIMS) vs Mattel Inc (MAT) Price & Performance

Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.

The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.

Mattel (MAT) trades at $16.69, up 1.95% with bullish technical signals from moving averages. The stock shows mixed earnings performance with recent misses but maintains solid profitability metrics including 7.78% net margin and 20.5% ROE. Recent CEO transition and takeover interest from Authentic Brands Group create significant market attention, though revenue has remained relatively flat around $5.4B annually.

The stock presents a balanced risk-reward profile with analyst consensus favoring Buy ratings (53%) but a $15 price target below current levels. Key opportunities include potential M&A activity and new leadership, while risks involve declining cash flows and competitive pressures in the toy industry. Valuation appears reasonable with P/E of 12.4x and P/S of 0.9x.